natgillin/translations-raw huggingface dataset:
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2): ≥ 104, 9 CCID50 na odmerek Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in sev FCV G1): ≥ 2, 0 enot v testu ELISA na odmerek Atenuirana Chlamydophila felis (sev 905): ≥ 103, 0 EID50 na odmerek
10 bottles of 1 dose (lyophilisate) and 10 bottles of 1ml (solvent)
10 stekleničk z 1 odmerkom (liofilizata) in 10 stekleničk po 1 ml (vehikla)
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2): ≥ 104, 9 CCID50 na odmerek Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in sev FCV G1): ≥ 2, 0 enot v testu ELISA na odmerke Atenuirana Chlamydophila felis (sev 905): ≥ 103, 0 EID50 na odmerek
Per 1-ml dose:
V odmerku po 1 ml:
Freeze-dried pellet:
Liofilizat:
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................. ≥ 104, 9 CCID501 Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1)......................... ≥ 2, 0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905)......................................................................... ≥ 103, 0 EID502 Pomožna snov:
Gentamicin, at most........................................................................................................................ .28 µg Solvent:
28 µg Vehikel:
Water for injection..................................................................................................................... q. s.
Voda za injiciranje........................................................................................................................ q. s.
1 ml 1: cell culture infective dose 50% 2: egg infective dose 50% For a full list of excipients, see section 6.1.
50% infektivni odmerek za embrionirana kokošja jajca
- against feline viral rhinotracheitis to reduce clinical signs,
- Proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj,
- against calicivirus infection to reduce clinical signs and excretion,
- Proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj in zmanjšanje izločanja virusov,
- against Chlamydophila felis infection to reduce clinical signs.
- Proti okužbam s Chlamydophila felis, za ublažitev kliničnih znamenj.
2/ 17 4.5 Special precautions for use
2/ 17 4. 5 Posebni previdnostni ukrepi
This vaccine should not be handled by persons who are immunodeficient or taking immunosuppressive drugs.
Oseba, ki daje zdravilo živalim, ne sme imeti oslabljenega imunskega sistema ali uživati zdravila, ki slabijo imunski sistem.
If self-injection occurs, immediate medical advice should be sought and the doctor informed that self-injection with a living chlamydial vaccine has occurred.
V primeru samo- injiciranja se takoj posvetujte z zdravnikom in mu povejte, da je prišlo do samo- injiciranja z živim cepivom, ki vsebuje klamidijo.
The reaction was transient
V zelo redkih primerih sta se en teden do tri tedne po ponovnem cepljenju pri odraslih mačkah pojavili prehodna hipertermija in letargičnost, včasih tudi v povezavi s šepanjem.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
4. 9 Odmerjanje in pot uporabe
Inject by subcutaneous route one 1-ml dose of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme:
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte 1- ml odmerek cepiva v podkožje, po naslednjem razporedu:
- first injection: from 8 weeks of age,
- prva injekcija od osmega tedna starosti naprej,
3 to 4 weeks later.
- druga injekcija 3 do 4 tedne pozneje.
In the presence of high levels of maternally derived specific antibodies, the primary vaccination course should be delayed until 12 weeks of age.
V primeru večjih količin maternalnih specifičnih protiteles, je treba osnovno cepljenje začeti pri 12 tednih starosti.
No effect other than those already mentioned in section “ Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
Izjemoma lahko povišana temperatura traja pet dni.
3/ 17 4.11 Withdrawal period(s)
3/ 17 4. 11 Karenca( e)
QI06AJ02
Oznaka ATC vet: QI06AJ02
Sucrose Sorbitol Dextran 40 Casein hydrolysate Collagen hydrolysate Salts
Sukroza Sorbitol Dextran 40 Hidrolizat kazeina Hidrolizat kolagena Soli
Do not mix with any other vaccine or immunological product, except those mentioned in section “ Interactions”.
Ne mešajte z nobenim drugim cepivom ali imunološkim izdelkom, razen s tistimi, ki so omenjeni v poglavju » Medsebojno delovanje «.
Use immediately after reconstitution
Uporabite takoj po rekonstituciji
Store and transport refrigerated (2 °C – 8 °C) protected from light.
Zaščitite pred svetlobo.
MERIAL 29, avenue Tony Garnier 69007 LYON FRANCE
MERIAL 29 avenue Tony Garnier 69007 LYON FRANCIJA
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu /.
6/ 17 A.
6/ 17 A IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Ime in naslov izdelovalcev biološke zdravilne učinkovine (zdravilnih učinkovin).
Name and address of the manufacturer(s) of the biological active substance(s) Merial Laboratory of Lyon Porte des Alpes Rue de l’ aviation 69800 SAINT-PRIEST France
Merial Laboratory of Lyon Porte des Alpes Rue de l’ aviation 69800 SAINT- PRIEST France
Merial Laboratory of Lyon Porte des Alpes Rue de l’ aviation 69800 SAINT-PRIEST France
Merial Laboratory of Lyon Porte des Alpes Rue de l’ aviation 69800 SAINT- PRIEST Francija
FHV (F2 strain)................................................................................................................ ≥ 104.9 CCID50 FCV (431 and G1 strains).............................................................................................. ≥ 2.0 ELISA U.
FHV (sev F2)..................................................................................................................... ≥ 104, 9 CCID50 FCV (seva 431 in G1)....................................................................................... ≥ 2, 0 enot v testu ELISA Chlamydophila felis.............................................................................................................. ≥ 103, 0 EID50 Gentamicin, največ...........................................................................................................................
EXP (mm/ yyyy) Use immediately after reconstitution.
EXP {mesec/ leto} Uporabite takoj po rekonstituciji.
Store and transport refrigerated (2 °C – 8 °C) protected from light.
Shranjujte in prevažajte pri temperaturi 2°C – 8°C (v hladilniku).
MERIAL 29, avenue Tony Garnier F-69007 LYON FRANCE
MERIAL 29 avenue Tony Garnier F- 69007 LYON FRANCIJA
EU/ 2/ 04/ 049/ 001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/ 2/ 04/ 049/ 002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/ 2/ 04/ 049/ 001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/ 2/ 04/ 049/ 002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
11/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
IZDELOVALČEVA ŠTEVILKA SERIJE IZDELAVE ZDRAVILA
Subcutaneous route
Subkutana pot
EXP (mm/ yyyy)
EXP (mesec/ leto)
Purevax RCCh Lyophilisate and solvent for suspension for injection.
Purevax RCCh Liofilizat in vehikel za suspenzijo za injiciranje
MERIAL 29, avenue Tony Garnier F-69007 Lyon France
Imetnik dovoljenja za promet z zdravilom MERIAL 29, avenue Tony Garnier F- 69007 Lyon Francija
MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
Imetnik dovoljenja za proizvodnjo zdravila, odgovoren za sprostitev serije MERIAL Laboratoire Porte des Alpes Rue de l' Aviation F- 69800 Saint Priest Francija
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................. ≥ 104, 9 CCID501 Inaktivirani antigeni kalici virusa mačk (seva FCV 431 in G1)....................... ≥ 2, 0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905)......................................................................... ≥ 103, 0 EID502 Pomožna snov:
Gentamicin, at most........................................................................................................................ .28 µg Solvent:
18 µg Vehikel:
Water for injection..................................................................................................................... q. s.
Voda za injiciranje......................................................................................................................... q. s.
1 ml 1: cell culture infective dose 50% 2: egg infective dose 50%
50% infektivni odmerek za celično kulturo 2:
- against feline viral rhinotracheitis to reduce clinical signs,
- Proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.
Imunost proti kužnemu rinotraheitisu, kalicivirozi mačk in Chlamydophila felis nastopi 1 teden po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination.
Živali so odporne eno leto po zadnjem cepljenju
- first injection: from 8 weeks of age,
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT( I) IN NAČIN UPORABE ZDRAVILA
- second injection:
Osnovno cepljenje:
In the presence of high levels of maternally derived specific antibodies, the primary vaccination course should be delayed until 12 weeks of age.
V primeru večjih količine maternalnih specifičnih protiteles, je treba osnovno cepljenje začeti pri 12 tednih starosti.
Revaccination:
Ponovno cepljenje: enkrat letno.
every year.
9.
Do not mix with any other vaccine or immunological product, except those mentioned below.
Ne mešajte z drugimi cepivi ali imunološkimi proizvodi, razen s spodaj navedenimi.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podatki o varnosti in učinkovitosti dokazujejo, da se lahko cepivo uporablja sočasno z Merialovim neadjuviranim cepivom proti mačji levkemiji in/ ali se ga lahko uporabi isti dan kot Merialovo adjuvirano cepivo proti steklini, vendar se ga ne sme mešati z omenjenim cepivom.
No effect other than those already mentioned in section “ Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days.
Izjemoma lahko povišana temperatura traja pet dni.
Purevax RCP is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated feline panleucopenia virus (PLI IV).
Zdravilo Purevax RCP je cepivo, ki vsebuje naslednje zdravilne učinkovine: • atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), • inaktivirane (uničene) antigene kalicivirusa mačk (seva FCV 431 in G1), • atenuirani virus panlevkopenije mačk (PLI IV).
Purevax RCP is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus), • feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus).
Zdravilo Purevax RCP se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim: • virusnemu rinotraheitisu mačk (gripi podobni bolezni, ki jo povzroča herpesvirus), • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus), • mačji panlevkopeniji (resni bolezni, ki povzroča krvavo drisko in jo povzroča parvovirus).
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How does Purevax RCP work?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Kako zdravilo Purevax RCP deluje?
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘ foreign’ and makes antibodies against them.
Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse kot „ tuje “ in proti njim izdela protitelesa.
In the field, the studies of Purevax RCP looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCP na terenu so preverili osnovni cepilni program (2 injekciji 3– 4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
Pharmaceutical Target
Farmacevtska
species administration
uporabe zdravila
Period
pakiranja
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose
Atenuirani herpes virus
Lyophilisate and solvent for suspension for injection
Liofilizat in
Type I glass bottle closed with a butyl elastomer closure and sealed with an aluminium cap
Prebodna
10 bottles of 1 dose (lyophilisate) and 10 bottles of 1ml (solvent)
10 stekleničk z
1 dose of lyophilisate and 1ml of solvent
1 odmerek
Not Applicable
Navedba ni
50 bottles of 1 dose (lyophilisate) and 50 bottles of 1ml (solvent)
50 stekleničk z
Purevax RCPCh is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated Chlamydophila felis (905 strain), • attenuated feline panleucopenia virus (PLI IV). • Purevax RCPCh is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Zdravilo Purevax RCPCh je cepivo, ki vsebuje naslednje zdravilne učinkovine: • atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), • inaktivirane (uničene) antigene kalicivirusa (sev FCV 431 in G1), • atenuirano bakterijo Chlamydophila felis (sev 905), • atenuirani virus panleukopenije mačk (PLI IV).
Purevax RCPCh is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus), • chlamydiosis (a flu-like illness caused by the bacterium C. felis), • feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus).
Zdravilo Purevax RCPCh se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim: • virusnemu rinotraheitisu mačk (gripi podobni bolezni, ki jo povzroča herpesvirus), • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus), • klamidiozi (gripi podobni bolezni, ki jo povzroča bakterija C. felis), • panleukopeniji mačk (resni bolezni, ki povzroča krvavo drisko in jo povzroča parvovirus).
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How does Purevax RCPCh work?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Kako zdravilo Purevax RCPCh deluje?
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses and the weakened bacteria as ‘ foreign’ and makes antibodies against them.
Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse in oslabljene bakterije kot „ tuje “ ter proti njim razvije protitelesa.
In the field, the studies of Purevax RCPCh looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCPCh na terenu so preučevali osnovno shemo cepljenja (2 injekciji 3– 4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RCPCh exceed the risks for the active immunisation of cats aged eight weeks or older against the diseases listed above, and recommended that Purevax RCPCh be given a marketing authorisation.
Zato je priporočil, da se za zdravilo Purevax RCPCh odobri dovoljenje za promet.
Invented
Izmišljeno Jakost ime
Pharmaceutical Target Route of
Ciljna živalska vrsta
Package
Vsebina (koncentracija)
Withdrawal
Velikost pakiranja
Name
Karenca
Form
1 odmerek
species administration
Navedba
(concentration)
Mačke
size
Subkutano
period
Prebodna
EU/ 2/ 04/ 050/ 001
Liofilizat in EU/ 2/ 04/ 050/ 001
Lyophilisate and solvent for suspension for injection
Atenuirani herpes virus
Cats
vehikel za
Subcutaneous use
steklenička
1 dose of Not lyophilisa applicable te and 1ml of solvent
1 odmerkom
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose
1 odmerkom
Lyophilisate and solvent for suspension for injection
liofilizata in
Cats
RCPCh
Subcutaneous use
suspenzijo za injiciranje
50 bottles of 1 dose (lyophilisate) and 50 bottles of 1ml (solvent)
(liofilizata) in 50 stekleničk po 1 ml (vehikla)
1 dose of Not lyophilisa applicable te and 1ml of solvent
1 ml vehikla
Purevax RCPCh FeLV is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated Chlamydophila felis (905 strain), • attenuated feline panleucopenia virus (PLI IV), • feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Zdravilo Purevax RCPCh FeLV je cepivo, ki vsebuje naslednje zdravilne učinkovine: • atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), • inaktivirane (uničene) antigene kalicivirusa (sev FCV 431 in G1), • atenuirano bakterijo Chlamydophila felis (sev 905), • atenuirani virus panleukopenije mačk (PLI IV), • rekombinantni poxvirus kanarčkov (vCP97), ki vsebuje antigen virusa mačje levkemije (FeLV).
Purevax RCPCh FeLV is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus), • chlamydiosis (a flu-like illness caused by the bacterium C. felis), • feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus), • feline leukaemia (an illness affecting the immune system caused by a retrovirus).
Zdravilo Purevax RCPCh FeLV se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim: • virusnemu rinotraheitisu mačk (gripi podobni bolezni, ki jo povzroča herpesvirus), • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus), • klamidiozi (gripi podobni bolezni, ki jo povzroča bakterija C. felis), • panleukopeniji mačk (resni bolezni, ki povzroča krvavo drisko in jo povzroča parvovirus), • mačji levkemiji (bolezni, ki prizadene imunski sistem in jo povzroča retrovirus).
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How does Purevax RCPCh FeLV work?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Kako zdravilo Purevax RCPCh FeLV deluje?
Purevax RCPCh FeLV contains small amounts of weakened or killed viruses and bacteria that cause the diseases listed above, as well as two genes from the FeLV called env and gag, which have been inserted into another vector (carrier) virus called canarypox using ‘ recombinant DNA technology’.
Zdravilo Purevax RCPCh FeLV vsebuje majhne količine oslabljenih ali uničenih virusov in bakterij, ki povzročajo zgoraj navedene bolezni, ter dva gena virusa FeLV, imenovana env in gag, ki so ju s „ tehnologijo rekombinantne DNA “ vstavili v drug virusni (prenašalni) vektor, imenovan poxvirus kanarčkov.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses, the FeLV proteins, and the weakened bacteria as ‘ foreign’ and makes antibodies against them.
Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse, beljakovine virusa FeLV in oslabljene bakterije kot „ tuje “ ter proti njim razvije protitelesa.
In the field, the studies of Purevax RCPCh FeLV looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and the booster vaccination (only one injection).
V študijah zdravila Purevax RCPCh FeLV na terenu so preučevali osnovno shemo cepljenja (2 injekciji 3– 4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
If self-injection does occur in these people, tell the doctor that self-injection with a living chlamydial vaccine has occurred.
V primeru nenamernega samoinjiciranja nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko na zunanji ovojnini.
Why has Purevax RCPCh FeLV been approved?
S cepivom ne smejo rokovati
The Committee for Medicinal Products
osebe, ki imajo oslabljen imunski sistem.
for Veterinary Use (CVMP) concluded that the
Zakaj je bilo zdravilo Purevax RCPCh FeLV odobreno?
benefits of Purevax RCPCh FeLV exceed the risks for the active immunisation of cats aged eight weeks or older against the diseases listed above, and recommended that Purevax RCPCh FeLV be given a marketing authorisation.
Zato je priporočil, da se za zdravilo Purevax RCPCh FeLV odobri dovoljenje za promet.
EU
EU številka
harmaceutical
Farmacevtska oblika
species
Ovojnina
EU/ 2/ 04/ 047/ 001
EU/ 2/ 04/ 048/ 001